Key Findings
The Europe nasal spray devices market is expected to proliferate at a CAGR of 6.53% during the forecasting period of 2019-2027. The market will be progressing mainly because of the investments made on the ongoing research and development activities for the advancement of generic nasal spray products.

Market Insights
The United Kingdom, France, Germany, Spain, Italy and the Rest of Europe are considered for the market analysis. The market in Germany is dominating the European market for nasal spray devices significantly. It is mainly driven by the high prevalence of allergies coupled with the high number of deaths due to air pollution.

A major challenge observed for the nasal spray devices market is patent expiration. In the past years, the pharmaceutical industry experienced several patent expiries and going through the patent cliffs.

Competitive Insights
Some of the market players mentioned in our report are Hikma Pharmaceuticals PLC, Pfizer, Inc., Becton Dickinson and Company, Merck & Co., Inc., Apotex, Sun Pharmaceuticals Industries, Ltd., Adapt Pharma, Inc. (acquired by Emergent BioSolutions), Beximco Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Cipla, Allergan Inc., Sanofi-Aventis S.A., Sandoz International GmbH (subsidiary of Novartis AG), Mylan NV and GlaxoSmithKline.